LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

CureVac NV

Closed

5.39

Overview

Share price change

24h

Current

Min

5.36

Max

5.39

Key metrics

By Trading Economics

Income

-8.3M

-60M

Sales

352K

1.2M

P/E

Sector Avg

5.4

35.724

Profit margin

-4,816.546

Employees

825

EBITDA

-8.2M

-55M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-2.78% downside

Dividends

By Dow Jones

Next Earnings

11 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-6.7M

1.2B

Previous open

5.39

Previous close

5.39

Technical Score

By Trading Central

Confidence

Bullish Evidence

CureVac NV Chart

Past performance is not a reliable indicator of future results.

Related News

12 Jun 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

12 Jun 2025, 13:34 UTC

Hot Stocks

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

Peer Comparison

Price change

CureVac NV Forecast

Price Target

By TipRanks

-2.78% downside

12 Months Forecast

Average 5.25 USD  -2.78%

High 5.5 USD

Low 5 USD

Based on 4 Wall Street analysts offering 12 month price targets forCureVac NV - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

0

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

3.47 / 3.755Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.